News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 361–396
- Matches
- 1294
- Sources here
- 17
- Companies here
- 16
Search results
Stored financial headlines
Active search
1294 matching headlines
Ticker or company: OPHMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma
Estrella Immunopharma has announced the activation of University Hospitals Cleveland Medical Center as the fourth clinical site for its STARLIGHT-1 Phase I/II clinical trial. This trial is evaluating EB103, an ARTEMIS® T-cell therapy targeting CD19, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. …
ESLA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -25.4% · Next-week setup negative 43.1%
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
Theravance Biopharma TBPH reported second-quarter 2026 adjusted earnings of 19 cents per share, matching the Zacks Consensus Estimate. In the year-ago quarter, the company had incurred an adjusted loss of 8 cents per share. Total revenues in the quarter were $20.7 million, marginally beating …
TBPH
main company
Sharemaestro market context
Price above Trend Line
52 weeks +22.0%
Estrella adds fourth site to EB103 lymphoma trial By Investing.com
Estrella Immunopharma Inc. (NASDAQ:ESLA) has activated a fourth clinical site, University Hospitals Cleveland Medical Center, for its STARLIGHT-1 Phase I/II trial of EB103. This trial evaluates EB103, a CD19-redirected T-cell therapy, for patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma. The company anticipates using …
ESLA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -25.4% · Next-week setup negative 43.1%
Vor Biopharma Inc. 2Q 2026: Net loss $(62.8M), EPS $(1.16) — 10-Q Summary
Vor Biopharma Inc. reported a second-quarter 2026 net loss of $(62.8M) and diluted net loss per share of $(1.16), showing a significant improvement compared to the year-ago quarter. The company recorded no product revenue as it focuses on late-stage development programs, specifically advancing global …
VOR
main company
Sharemaestro market context
Trend signal active
52 weeks -46.9% · Next-week setup negative 38.4%
HC Wainwright Estimates Immix Biopharma FY2027 Earnings
HC Wainwright forecasts Immix Biopharma (NASDAQ: IMMX) to report a loss of $0.20 per share for FY2027, maintaining a "Buy" rating and a $25 price target. This contrasts with the current consensus estimate of a $0.69 loss per share. The company recently reported a …
IMMX
main company
Sharemaestro market context
Trend signal active
52 weeks +400.9%
ConocoPhillips (NYSE:COP) Given New $161.00 Price Target at Susquehanna
Susquehanna has increased its price target for ConocoPhillips (NYSE:COP) to $161.00 from $155.00, maintaining a "positive" rating on the stock, implying a potential upside of 31.02%. This update follows ConocoPhillips' strong second-quarter results, where it surpassed earnings and revenue estimates and increased shareholder distributions. …
COP
main company
Sharemaestro market context
Trend signal started
52 weeks +34.2%
Mereo BioPharma Reports Second Quarter 2026 Financial Results and Provides Corporate Highlights
Mereo BioPharma Group plc Entered into option and license agreement with Sentynl Therapeutics for alvelestat, Mereo's investigational oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease (AATD-LD) Mereo and partner Ultragenyx engaging with regulatory agencies on potential path forward for setrusumab in osteogenesis imperfecta (OI); …
MREO
main company
Sharemaestro market context
Price below Trend Line
52 weeks -81.2% · Next-week setup negative 42.7%
Theravance Biopharma, Inc. 2026: Revenue $20.73M, EPS ($0.11) — 10-Q Summary
Theravance Biopharma, Inc. (TBPH) reported its 2026 quarterly results, showing a significant decrease in revenue and a net loss compared to the prior year. Revenue dropped by 20.9% to $20.73M, resulting in a diluted EPS of ($0.11) versus $1.08 previously, largely due to the …
TBPH
main company
Sharemaestro market context
Price above Trend Line
52 weeks +22.0%
Mereo BioPharma Group plc Q2 2026: Revenue $0 Net loss $7.01M, EPS $(0.01) — 10-Q Summary
Mereo BioPharma Group plc (MREO) reported financial results for Q2 2026, showing $0 revenue and a net loss of $7.005 million, or $(0.01) per diluted share, which is an improvement compared to the $14.616 million net loss in Q2 2025. The company's business highlights …
MREO
main company
Sharemaestro market context
Price below Trend Line
52 weeks -81.2% · Next-week setup negative 42.7%
Mereo BioPharma licenses alvelestat to Sentynl Therapeutics
Mereo BioPharma has entered into an option and license agreement with Sentynl Therapeutics for alvelestat, an oral therapy for Alpha-1 Antitrypsin Deficiency-Associated Lung Disease. Under the agreement, Mereo could receive a non-refundable option fee, $40 million in upfront and R&D payments upon option exercise, …
MREO
main company
Sharemaestro market context
Price below Trend Line
52 weeks -81.2% · Next-week setup negative 42.7%
How Q2 2026 Results and New Leadership At ConocoPhillips (COP) Has Changed Its Investment Story
ConocoPhillips (COP) reported strong Q2 2026 results, including US$19.52 billion in revenue and US$3.93 billion in net income, alongside a US$0.84 per-share dividend and ongoing share repurchases. The company also announced a leadership transition, with CEO Ryan Lance becoming executive chair and CFO Andy …
COP
main company
Sharemaestro market context
Trend signal started
52 weeks +34.2%
Immix Biopharma publishes corporate presentation on NXC-201 BCMA CAR-T in relapsed/refractory AL amyloidosis
Immix Biopharma has published a corporate presentation detailing its lead program, NXC-201 BCMA CAR-T, for relapsed or refractory AL amyloidosis. The presentation highlights a 95% complete response rate for NXC-201 from its NEXICART-2 U.S. phase 1/2 trial, which has completed enrollment with 45 patients. …
IMMX
main company
Sharemaestro market context
Trend signal active
52 weeks +400.9%
Susquehanna Adjusts PT on ConocoPhillips to $161 From $155, Maintains Positive Rating
Susquehanna has increased its price target for ConocoPhillips (COP) from $155 to $161, while maintaining a positive rating on the stock. This adjustment reflects a continued optimistic outlook from the analyst firm for the oil and gas exploration and production company. The article also …
COP
main company
Sharemaestro market context
Trend signal started
52 weeks +34.2%
Cue Biopharma (CUE) Expected to Announce Earnings on Tuesday
Cue Biopharma (NASDAQ:CUE) is set to release its Q2 2026 earnings before market open on Tuesday, August 18th. Analysts anticipate a loss of $1.69 per share and $3.00 million in revenue. The company previously exceeded expectations in Q1, reporting a smaller loss and higher …
CUE
main company
Sharemaestro market context
Trend signal active
52 weeks +38.0% · Next-week setup negative 44.6%
Goldman Sachs Adjusts Price Target on ConocoPhillips to $146 From $140, Keeps Buy Rating
Goldman Sachs has raised its price target for ConocoPhillips (COP) to $146 from $140, while maintaining a Buy rating on the stock. This adjustment comes amidst other analyst revisions for ConocoPhillips, with several firms reiterating Buy or Outperform ratings with varied price target changes. …
COP
main company
Sharemaestro market context
Trend signal started
52 weeks +34.2%
Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside
Immix Biopharma, Inc. (IMMX) has seen its average 12-month price target adjusted down slightly from $20.56 to $20.44 by 8 analysts. Despite the minor cut, the new target still implies a significant 102% potential upside from its Aug. 10 closing price. The consensus rating …
IMMX
main company
Sharemaestro market context
Trend signal active
52 weeks +400.9%
Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating
Morgan Stanley has adjusted its price target for Immix Biopharma (IMMX) to $19, down from $20, while maintaining an Overweight rating on the stock. This update comes after the company recently reported its earnings results for the second quarter and six months ended June …
IMMX
main company
Sharemaestro market context
Trend signal active
52 weeks +400.9%
Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH
Renaissance Technologies LLC has acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH), purchasing 127,916 shares valued at approximately $2.076 million. This makes Renaissance Technologies LLC one of many institutional investors with holdings in TBPH, as they collectively own 99.10% of the company's stock. …
TBPH
main company
Sharemaestro market context
Price above Trend Line
52 weeks +22.0%
Key facts: ConocoPhillips names CEO; Truist PT $130; Sen. flags windfall
ConocoPhillips has appointed CFO Andy O'Brien as its new CEO, effective September 1, with Ryan Lance becoming executive chairman. Truist raised its price target for ConocoPhillips (COP) to $130 from $115. Senator Elizabeth Warren has accused ConocoPhillips of recording "windfall profits" linked to geopolitical …
COP
main company
Sharemaestro market context
Trend signal started
52 weeks +34.2%
Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Theravance Biopharma, Inc. (TBPH) reported its second quarter 2026 financial results, highlighting a significant 15% increase in total revenue year-over-year, reaching $40 million. The company's net loss decreased by 10% to $18 million, or $0.30 per share, demonstrating improved financial performance. Key updates included …
TBPH
main company
Sharemaestro market context
Price above Trend Line
52 weeks +22.0%